Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer ; volume:15 ; number:1 ; day:1 ; month:5 ; year:2015 ; pages:1-10 ; date:12.2015
BMC cancer ; 15, Heft 1 (1.5.2015), 1-10, 12.2015
- Urheber
-
Bondarenko, Igor M.
- Beteiligte Personen und Organisationen
-
Ingrosso, Antonella
Bycott, Paul
Kim, Sinil
Cebotaru, Cristina L.
SpringerLink (Online service)
- DOI
-
10.1186/s12885-015-1350-6
- URN
-
urn:nbn:de:1111-2016110618720
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:03 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bondarenko, Igor M.
- Ingrosso, Antonella
- Bycott, Paul
- Kim, Sinil
- Cebotaru, Cristina L.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy
The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer
Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer
Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer
Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC
Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC
Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
Molecular patterns of egyptian patients with non-squamous non-small-cell lung cancers: a clinicopathological study
A scotogenic model with two inert doublets
Effective field theory with two Higgs doublets
Chemotherapy with cisplatin and vinorelbine for elderly patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC)
Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy
The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer
Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer
Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer
Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC
Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC
Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
Molecular patterns of egyptian patients with non-squamous non-small-cell lung cancers: a clinicopathological study
A scotogenic model with two inert doublets
Effective field theory with two Higgs doublets
Chemotherapy with cisplatin and vinorelbine for elderly patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC)
Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy
The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer
Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer
Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer
Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC
Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC
Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
Molecular patterns of egyptian patients with non-squamous non-small-cell lung cancers: a clinicopathological study
A scotogenic model with two inert doublets
Effective field theory with two Higgs doublets